摘要
目的研究头孢哌酮舒巴坦在重症监护病房(ICU)脓毒症患者体内的药代动力学。方法选择2017年1~9月在浙江省瑞安市人民医院成人ICU诊断为脓毒症且初次使用头孢哌酮舒巴坦针2.0g的患者,采集头孢哌酮舒巴坦输注第一剂之前和完毕后0、0.25、0.5、1、2、3、4、6、8h的血样,分离血清,用高效液相色谱(HPLC)法测定其血药浓度。结果头孢哌酮消除半衰期(t1/2):(1.575±0.325)h,清除率(CL):(0.095±0.023)L/(h·kg),表观分布容积(Vd):(0.215±0.037)L/kg,峰浓度(Cmax):(83.633±19.324)mg/L,药时曲线下面积[AUC(0→∞)]:(190.213±42.625)h·mg/L;舒巴坦t1/2:(1.049±0.263)h,CL:(0.281±0.065)L/(h·kg),Vd:(0.424±0.103)L/kg,Cmax:(42.526±11.210)mg/L,AUC(0→∞):(64.394±15.435)h·mg/L。结论 ICU脓毒症患者头孢哌酮的Vd与文献报道的普通成年人稍大,Cmax稍低,t1/2稍短,舒巴坦的变化相对较小,因此其使用头孢哌酮时要提高给药剂量和缩短给药时间。
Objective To investigate the pharmacokinetics of Cefoperazone/Sulbactam in intensive care unit patients with sepsis. Methods The patients with sepsis in intensive care unit of Ruian people′ s Hospital of Zhejiang Province from January to September 2017 who was administered 2.0g Cefoperazone/Sulbactam for the first time were inrolled.Serial serum samples were collected before the first antibiotic dose and at 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8h after Cefoperazone/Sulbactam was administered. Then the serum was separated and the concentration was determined by HPLC. Results Cefoperazone： half-life（t1/2）：（1.575±0.325）h, clearance rate（CL）：（0.095±0.023）L/（h·kg）, apparent volume of distribution（Vd）：（0.215±0.037） L/kg, peak concentration（Cmax）：（83.633 ±19.324）mg/L, area under the curve AUC（0→∞）：（190.213±42.625）h·mg/L; Sulbactam： t1/2：（1.049±0.263）h, CL：（0.281±0.065）L/（h·kg）, Vd：（0.424±0.103）L/kg,Cmax：（42.526±11.210）mg/L, AUC（0→∞）：（64.394±15.435）h·mg/L. Conclusion The apparent volume of distribution of Cefoperazone in intensive care unit patients with sepsis is slightly larger than that reported in the literature, the peak concentration is slightly lower, and the half-life is shorter, while the change of Sulbactam is relatively small. Therefore,the dosage of Cefoperazone should be improved and the dosing interval should be shortened in those patients.
作者
易林高
陈晓孩
何国鑫
陈杰
林洁
YI Lingao ,CHEN Xiaohai, HE Guoxin ,CHEN Jie ,LIN Jie(Department of Pharmacy, tluian People＇s Hospital, Zhejiang Province, Ruian 325200, Chin)
出处
《中国医药导报》
CAS
2018年第10期34-37,41,共5页
China Medical Herald
基金
浙江省温州科技计划项目(Y20160536)
